CD90参与浆液性卵巢癌干细胞筛选及干细胞相关耐药的机制研究

化疗耐药是肿瘤复发致死的关键因素，在卵巢癌中尤为明显。研究表明，肿瘤干细胞在肿瘤耐药中扮演了重要角色，因此鉴定卵巢癌干细胞，探索新的干预靶点，对于解决卵巢癌耐药具有较大的临床价值。我们的前期研究发现CD90高表达的浆液性卵巢癌细胞具有干细胞属性且明显耐药，通过制备CD90封闭抗体能够缓解体外培养浆液性卵巢癌细胞的耐药。在前期研究的基础上，我们拟在细胞和整体水平验证CD90是否可作为浆液性卵巢癌干细胞鉴定的分子靶标，及其在卵巢癌干细胞属性维持及化疗耐药中发挥的作用和具体机制，为进一步研究卵巢癌分子分型及临床靶向治疗提供理论依据。

Resistance to chemotherapy is the main causal factor for cancer-related mortality, especially in ovarian cancer patients. Since several lines of evidences suggested that cancer stem cell plays an important role in drug resistance, it is of great importance to identify these cancer stem cells and their corresponding specific marker so that strategies targeting these cancer stem cells could be developed to treat the drug resistance of ovarian cancer. In previous research, we confirmed that cells with high expression of CD90 showed the property of stem cells and were resistant to cisplatin-based chemotherapy. CD90-blocking antibody could be used to treat drug resistance of ovarian cancer cells. Based on our previous data, this project is designed to investigate whether CD90 could be a specific marker and also a target for serous epithelial oviran cancer stem cells. We will perform experiments to explore the underlying mechanisms for CD90’s potentials to maintain the state of ovarian cancer stem cells, and to investigate the singaling pathways responsible for CD90-related drug resistance in ovarian cancers. Our project will provide new insight for the molecular-classification of ovarian cancers as well as cancer stem cell based therapy.